What is the name of your organization?
BrainCapture
What is the name of your solution?
BrainCapture's BC-1 Solution
Provide a one-line summary or tagline for your solution.
An affordable, AI-driven EEG device that brings life-saving neurological diagnostics to vulnerable populations worldwide.
In what city, town, or region is your solution team headquartered?
Copenhagen, Denmark
In what country is your solution team headquartered?
DNK
What type of organization is your solution team?
For-profit, including B-Corp or similar models
Film your elevator pitch.
What specific problem are you solving?
Epilepsy is the most common neurological disorder globally, affecting over 50 million people and contributing to 1% of the global disease burden. Nearly 80% of people living with epilepsy (PLWE) reside in low- and middle-income countries (LMICs), where risk factors like perinatal injury, head trauma, and CNS infections are more prevalent (WHO, 2022; Muhigwa et al., 2020). In rural areas, these risks are exacerbated (Matuja et al., 2001).
Children under 10 are disproportionately affected. The global burden of disease study reports peak prevalence (374.8 per 100,000) and years lived with disability in the 5–9 age group, with the highest years of life lost in children under five (GBD Epilepsy Collaborators, 2016). In Kenya, prevalence in children is estimated at 21–41 per 1,000 (Samia et al., 2019), with regional estimates as high as 31 per 1,000 (Kariuki et al., 2021).
Despite this, many go undiagnosed due to stigma, poor surveillance, and limited access to diagnostics. In Kenya, only 24 neurologists serve over 53 million people (Myer et al., 2016). Yet 70% of PLWE could live seizure-free with early diagnosis and affordable treatment (WHO, 2022; Steenkiste et al., 2019), highlighting a critical diagnostic gap that the BC-1 solution addresses.
What is your solution?
BrainCapture’s BC-1 is an affordable, portable EEG solution that enables accurate neurological diagnosis without requiring on-site specialists.
The system includes:
A CE-marked EEG device (amplifier + electrode cap) that captures hospital-grade brain activity data;
A smartphone app that guides non-specialist healthcare workers through setup and recording;
A cloud-based telemedicine platform that securely transmits EEG data to remote neurologists for diagnosis.
Designed for low-resource settings, the BC-1 is durable, battery-powered, and requires minimal training to operate. Unlike traditional EEG machines costing $20,000–$35,000, the BC-1 is priced around $5,000 and eliminates the need for expensive EEG technologists.
How it works:
A healthcare worker fits the electrode cap and initiates recording via the app. EEG data is transmitted securely to a remote server. A remote neurologist analyzes the data and sends a report back to the clinic within 2 hours, enabling rapid intervention. Soon, an AI diagnostic model will be integrated to assist with automated EEG interpretation, further accelerating diagnosis and expanding access in settings without specialist availability.
The BC-1 is already deployed in Kenya, Malaysia, Indonesia, and the Philippines where we've served 1,500+ patients to date. By 2027, we aim to reach 500,000+ patients annually.
Watch the product demo here: https://www.youtube.com/watch?v=Qxl9swAaFb8
Who does your solution serve, and in what ways will the solution impact their lives?
Our solution serves people living with epilepsy in LMICs, where access to neurological diagnostics is severely limited. Children are particularly underserved, as epilepsy disproportionately affects this demographic, with global prevalence peaking at 374.8 per 100,000 in the 5–9 age group (GBD, 2016). In Kenya alone, where over 20 million children are under the age of 14 and there is only 1 neurologist per 2.5 million people, the unmet need is enormous. In the Philippines, over 1 million people live with epilepsy, but only 20 epileptologists are available nationally (Moalong et al., 2020).
Barriers include the high cost of EEG machines, lack of trained personnel, and geographic distance from urban hospitals. These prevent timely diagnosis and treatment, especially in rural areas.
The BC-1 addresses these challenges by offering a low-cost, portable, AI-enabled EEG system operable by non-specialist healthcare workers. It brings diagnostics to the point of care, reducing costs and wait times. Our cloud-based platform enables remote neurologist review and ongoing care.
By decentralizing access to diagnosis and supporting continuity of care, the BC-1 improves health outcomes, reduces disability and stigma, minimizes household healthcare expenditure, and empowers local health systems, ultimately advancing health equity for communities historically excluded from specialized care.
